Sentinel API Group

Sentinel restores U.S. production of essential generic APIs by retrofitting modular, federally aligned GMP facilities that are DMF-ready from day one and designed to pair equity with matching grants for resilient domestic supply.

Sentinel solves the collapse of U.S. generic API manufacturing, where 92% of top antibiotics have no domestic source and national capacity has fallen to <2% of former output, leaving the country dependent on fragile offshore supply chains. We rebuild this capability by retrofitting federally aligned, grant-leveraged GMP facilities that produce essential APIs domestically and meet new OBBB and SAPIR procurement mandates.

Sentinel restores U.S. API manufacturing by retrofitting modular, federally aligned GMP facilities that produce DMF-ready essential generics without R&D lag. The model pairs equity with matching federal grants and meets new OBBB/SAPIR procurement mandates to rebuild reliable, domestic pharmaceutical supply.